Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K

Rhea-AI Summary

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) filed its annual report on Form 10-K for the fiscal year ending December 31, 2020, reporting a net loss of approximately $7.4 million from continuing operations, down slightly from $7.5 million in 2019. The discontinued operations incurred a net loss of $10.8 million, compared to $9.0 million in the prior year. Cash and cash equivalents stood at $5.4 million at year-end, supplemented by $8.9 million from a January 2021 offering, expected to sustain operations into Q1 2022. The company continues to focus on early-stage product development following its strategic restructuring.

Positive

• Net loss from continuing operations decreased from $7.5 million in 2019 to $7.4 million in 2020.
• Cash and equivalents of $5.4 million plus $8.9 million from January 2021 offering provide sufficient funding into Q1 2022.

Negative

• Net loss from discontinued operations increased from $9.0 million in 2019 to $10.8 million in 2020.
• The company has discontinued U.S. Probuphine implant sales and commercialization activities.

SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission ("SEC").

In October 2020, Titan announced a strategic restructuring, including the discontinuation of its U.S. Probuphine® implant sales and the wind down of Probuphine commercialization activities. This was shortly followed with its acquisition of a kappa opioid agonist peptide, or TP-2021 (formerly JT-09), and the settlement of substantially all of its outstanding debt, all of which has enabled the Company to pursue a plan focused on its current, early-stage ProNeura®-based product development programs.

As a result of this restructuring, the financial statements in Titan's Form 10-K reflect results of operations from both continuing and discontinued operations.

Titan's net loss from continuing operations for the year ended December 31, 2020 was approximately $7.4 million, or approximately $1.96 per share, compared to a net loss from continuing operations of approximately $7.5 million, or approximately $9.78 per share, for the comparable period in 2019. The net loss from discontinued operations for the year ended December 31, 2020 was approximately $10.8 million, or approximately $2.87 per share, compared to a net loss from discontinued operations of approximately $9.0 million, or approximately $11.71 per share, for the comparable period in 2019.

At December 31, 2020, Titan had cash and cash equivalents of approximately $5.4 million, which the Company believes, together with the approximately $8.9 million of the net proceeds from its January 2021 Offering, are sufficient to fund its planned operations into the first quarter of 2022.

"As a result of our transition from a commercial-stage back to a development-stage company, we have discontinued hosting quarterly investor conference calls. Of course, Titan remains committed to disclosing all material news and information in a timely manner, and we look forward to updating investors accordingly as we move forward," said Marc Rubin, M.D., Titan's Executive Chairman.

A copy of Titan's annual report is available on the SEC's website at www.sec.gov, and on the Company's website at www.titanpharm.com under "Annual Reports" in the Investors section.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating  a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.  

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the winding down of U.S. commercial activities related to Probuphine, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

CONTACT:

Stephen Kilmer
Investor Relations
(650) 989-2215
skilmer@titanpharm.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/titan-pharmaceuticals-announces-filing-of-2020-annual-report-on-form-10-k-301260038.html

SOURCE Titan Pharmaceuticals, Inc.

FAQ

What were Titan Pharmaceuticals' net losses for 2020?

Titan reported a net loss of approximately $7.4 million from continuing operations and $10.8 million from discontinued operations for the year ended December 31, 2020.

What is the cash situation for Titan Pharmaceuticals as of December 31, 2020?

As of December 31, 2020, Titan had cash and cash equivalents of approximately $5.4 million, supplemented by $8.9 million from a January 2021 offering, expected to fund operations into Q1 2022.

What strategic changes did Titan Pharmaceuticals implement in 2020?

In 2020, Titan discontinued its U.S. Probuphine implant sales, wound down Probuphine commercialization activities, and focused on early-stage ProNeura-based product development.

How did Titan's net loss per share change from 2019 to 2020?

The net loss per share from continuing operations decreased from approximately $9.78 in 2019 to $1.96 in 2020.

Is Titan Pharmaceuticals still hosting investor calls?

Titan has discontinued hosting quarterly investor conference calls due to its transition to a development-stage company.